HC Wainwright Analysts Raise Earnings Estimates for CVE:SLS

Solaris Resources Inc. (CVE:SLS) – Equities researchers at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of Solaris Resources in a report issued on Monday, April 13th. HC Wainwright analyst H. Ihle now anticipates that the company will post earnings of ($0.47) per share for the year, up from their previous forecast of ($0.48).

Solaris Resources Price Performance

SLS opened at C$6.15 on Wednesday. The business has a 50 day moving average of C$6.15 and a 200-day moving average of C$6.15. Solaris Resources has a 1-year low of C$1.38 and a 1-year high of C$7.09.

Solaris Resources Company Profile

SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer.